Top-News
Dienstag,
16.07.2019 12:41
von
PR Newswire
| Aufrufe: 177
Johnson & Johnson Reports 2019 Second-Quarter Results
10 Downing Street, die Residenz des britischen Premierministers in London.
© palinchakjr / iStock Editorial / Getty Images Plus / Getty Images
http://www.gettyimages.de
PR Newswire
NEW BRUNSWICK, N.J., July 16, 2019
NEW BRUNSWICK, N.J., July 16, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2019. "We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses," said Alex Gorsky, Chairman and Chief Executive Officer. "Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world."
OVERALL FINANCIAL RESULTS:
| | SECOND QUARTER | | |
| ($ in Millions, except EPS) | 2019 | 2018 | % Change |
| Reported Sales | $ 20,562 | $ 20,830 | (1.3)% |
| Net Earnings | 5,607 | 3,954 | 41.8% |
| EPS (diluted) | $ 2.08 | $ 1.45 | 43.4% |
| | | | |
| Non-GAAP* | SECOND QUARTER | | |
| ($ in Millions, except EPS) | 2019 | 2018 | % Change |
| Operational Sales1,2 | N/A | N/A | 01.6% |
| Adjusted Operational Sales1,3 | N/A | N/A | 03.7% |
| Adjusted Net Earnings1,4 | 6,950 | 5,718 | 21.5% |
| Adjusted EPS (diluted)1,4 | $ 2.58 | $ 2.10 | 22.9% |
| 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |||
| 2 Excludes the impact of translational currency | |||
| 3 Excludes the net impact of acquisitions and divestitures and translational currency | |||
| 4 Excludes intangible amortization expense and special items | |||
REGIONAL SALES RESULTS:
| | SECOND QUARTER | % Change | ||||
| ($ in Millions) 1 | 20192 | 20182 | Reported2 | Operational1,2 | Currency2 | Adjusted Operational1,3 |
| U.S. | $ 10,403 | $ 10,640 | (2.2)% | (2.2) | - | 0.0 |
| International | 10,159 | 10,190 | (0.3)% | 5.5 | (5.8) | 7.6 |
| Worldwide | $ 20,562 | $ 20,830 | (1.3)% | 1.6 | (2.9) | 3.7 |
| 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | ||||||
| 2 Excludes the impact of translational currency | ||||||
| 3 Excludes the net impact of acquisitions and divestitures and translational currency | ||||||
| Note: values may have been rounded | ||||||
SEGMENT SALES RESULTS:
| | SECOND QUARTER | % Change | ||||
| ($ in Millions) 1 | 20191 | 20181 | Reported2 | Operational1,2 | Currency1 | Adjusted Operational1,3 |
| Consumer | $ 3,544 | $ 3,504 | 1.2% | 4.6 | (3.4) | 2.3 |
| Pharmaceuticals Werbung Mehr Nachrichten zur Johnson & Johnson Corp. Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||||||
